On March, 20 is anticipated NuCana plc (NASDAQ:NCNA)’s earnings report, according to RTT. 100.00 % negative EPS growth is what Wall Street’s sees after $-0.10 reported EPS last quarter. Ticker’s shares touched $13 during the last trading session after 6.21% change.NuCana plc has 141,104 shares volume, 95.90% up from normal. NCNA is downtrending and has moved 29.70% since March 11, 2018. NCNA underperformed by 34.07% the S&P500.

NuCana plc, a clinical-stage biopharmaceutical company, engages in the development of products for the treatment of cancer.The firm is valued at $411.91 million. It is developing Acelarin that is in Phase I clinical trials for the treatment of advanced metastatic solid tumors; Phase Ib clinical trials for the treatment of recurrent ovarian cancer; Phase II clinical trials for the treatment of patients with platinum-resistant ovarian cancer; and in Phase Ib clinical trials for the treatment of patients with biliary cancer.Currently it has negative earnings. The firm is also developing NUC-3373, a ProTide transformation of the active anti-cancer metabolite of 5-fluorouracil, which is in Phase I clinical trial for the treatment of patients with advanced solid tumors; and NUC-7738, a nucleoside analog that is in preclinical studies for the treatment of solid tumors and hematological malignancies.

For more NuCana plc (NASDAQ:NCNA) news released recently go to: Globenewswire.com, Globenewswire.com, Nasdaq.com, Nasdaq.com or Nasdaq.com. The titles are as follows: “NuCana Announces First Patients Enrolled in Phase Ib Study of NUC-3373 in Advanced Colorectal Cancer – GlobeNewswire” released on November 01, 2018, “NuCana plc Announces Withdrawal of Public Offering of ADSs – GlobeNewswire” on January 25, 2019, “ADXS Cervical Cancer Trial Put On Hold, GIS Recalls Flour, NCNA, URGN Slump – Nasdaq” with a publish date: January 23, 2019, “European ADRs Move Lower in Thursday Trading – Nasdaq” and the last “European ADRs Edge Lower in Wednesday Trading – Nasdaq” with publication date: March 06, 2019.